InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.450 0.02 (4.65%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$216 US Clinical Trial of VivaGel for Genital Herpes Commences 24 Oct 2006 11:04AM $0.590 $0.450 fallen by 23.73%
$216 To Acquire Dendritic Nanotechnologies Inc 4 Oct 2006 10:03AM $0.540 $0.450 fallen by 16.67%
$216 Trading Halt 3 Oct 2006 10:51AM $0.495 $0.450 fallen by 9.09%
$216 Investee Company DNT announces NCI Contract 29 Sep 2006 10:50AM $0.480 $0.450 fallen by 6.25%
$216 Preliminary Final Report 7 Sep 2006 9:56AM $0.460 $0.450 fallen by 2.17%
$216 Initiates NIH-funded human trial for VivaGel 24 Aug 2006 10:15AM $0.500 $0.450 fallen by 10%
$216 Commitments Test Entity - Fourth Quarter Report 28 Jul 2006 9:49AM $0.500 $0.450 fallen by 10%
$216 VivaGel IND for Genital Herpes Trial clears US FDA 19 Jul 2006 10:54AM $0.500 $0.450 fallen by 10%
$216 IND Lodged with FDA for VivaGel Genital Herpes Trial 26 Jun 2006 9:58AM $0.380 $0.450 risen by 18.42%
$216 VivaGel is a Potent Contraceptive in Animal Model 14 Jun 2006 8:39AM $0.395 $0.450 risen by 13.92%
$216 Commitments Test Entity - Third Quarter Report 27 Apr 2006 12:36PM $0.505 $0.450 fallen by 10.89%
$216 NIH Funds Clinical Development of VivaGel for Genital Herpes 20 Apr 2006 9:55AM $0.515 $0.450 fallen by 12.62%
$216 Increasing US investment support for Starpharma 6 Apr 2006 10:04AM $0.490 $0.450 fallen by 8.16%
$216 Half Yearly Report & Half Year Accounts 9 Mar 2006 2:52PM $0.490 $0.450 fallen by 8.16%
$216 Commitments Test Entity - Second Quarter Report 31 Jan 2006 1:38PM $0.500 $0.450 fallen by 10%
$216 Vivagel receives Fast Track Status from FDA 9 Jan 2006 9:42AM $0.515 $0.450 fallen by 12.62%
$216 Reinstatement to Official Quotation 14 Nov 2005 5:09PM n/a $0.450 n/a
$216 Raises A$15m Through Institutional Placement & SPP 14 Nov 2005 5:07PM n/a $0.450 n/a
$216 Suspension from Official Quotation 11 Nov 2005 9:27AM n/a $0.450 n/a
$216 Trading Halt 9 Nov 2005 9:58AM n/a $0.450 n/a
$216 Commitments Test Entity - First Quarter Report 31 Oct 2005 11:59AM $0.590 $0.450 fallen by 23.73%
$216 US Associate DNT Major Collaboration with NCL 11 Oct 2005 1:09PM $0.630 $0.450 fallen by 28.57%
$216 Secures full ownership of core technology 11 Oct 2005 8:29AM $0.630 $0.450 fallen by 28.57%
$216 VivaGel development accelerated with US$20m funding from NIH 3 Oct 2005 9:28AM $0.655 $0.450 fallen by 31.30%
$216 Trading Halt 30 Sep 2005 9:52AM n/a $0.450 n/a

851 - 875 of 902 results

Page 35 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.